{"disease":{"id":"non-hodgkin-s-lymphoma-relapsed","name":"non hodgkin s lymphoma relapsed"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06119685","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05798897","title":"Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":79,"lead_sponsor_name":"Marker Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03623087","title":"SIMPLE Chemotherapy for NK Lymphoma/Leukaemia","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06082596","title":"Study of BEBT-908 in Subjects With Advanced Hematological Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"BeBetter Med Inc","has_results":false},{"nct_id":"NCT05650580","title":"TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Tarapeutics Science Inc.","has_results":false},{"nct_id":"NCT06343311","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Estrella Biopharma, Inc.","has_results":false},{"nct_id":"NCT03091933","title":"Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ciusss de L'Est de l'Île de Montréal","has_results":false},{"nct_id":"NCT05360238","title":"Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT05618925","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT04030195","title":"Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Precision BioSciences, Inc.","has_results":true},{"nct_id":"NCT07478848","title":"Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT03774654","title":"CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT05054257","title":"CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT03488251","title":"PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Molecular Templates, Inc.","has_results":true},{"nct_id":"NCT04844086","title":"RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Eden BioCell Ltd.","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}